Clinical Trials Browser

Phase 1/2 × Active not recruiting × Other solid neoplasm × Clear all

NCT01064648 2026-03-18

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Phase 1/2 Active not recruiting

117 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT02535312 2026-03-18

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1/2 Active not recruiting

30 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT06057922 2026-03-12

A Study YL201 in Patients With Selected Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07461181 2026-03-10

A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT02285816 2026-03-09

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced/Metastatic Solid Tumours

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT05951608 2026-03-05

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06685068 2026-03-03

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03917381 2026-02-11

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT05518045 2026-02-04

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05744427 2026-02-02

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05163041 2026-01-15

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT04725474 2026-01-12

GDFATHER

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT06631079 2026-01-08

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05886920 2025-12-15

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors With MAPK Pathway Mutations

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06345482 2025-11-20

A Study of MHB039A for Advanced Solid Tumor

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06373406 2025-11-19

A Study of MHB036C for Advanced Solid Tumor

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT01375114 2025-10-28

The Effects of Ginseng on Cancer-Related Fatigue

Phase 1/2 Active not recruiting

165 enrolled 14 charts

Other solid neoplasm

Advanced Cancers

NCT06873789 2025-10-15

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT02414269 2025-10-08

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1/2 Active not recruiting

BreastOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis

NCT06260774 2025-10-02

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06385678 2025-09-19

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced KRAS G12D Mutant Solid Tumors

NCT04632108 2025-09-11

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Malignant Solid Tumor

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06480240 2025-08-08

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05275777 2025-07-25

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Phase 1/2 Active not recruiting

BreastOther solid neoplasm

HER2-negative Breast Cancer

NCT04322006 2025-05-22

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05379946 2025-04-08

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT04585035 2025-03-18

Study to Evaluate D-1553 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasmThoracic

Solid Tumor, Adult

NCT05990452 2024-11-21

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 1/2 Active not recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05765032 2024-09-26

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05399654 2024-08-16

INCLINE-101

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced or Metastatic Solid Tumors